Who
Christopher W. Cain
Director
Company insider
Files Form 4 as: Director, Viridian Therapeutics; Director, Cogent Biosciences; Director, Jade Biosciences; Director, Damora Therapeutics.
In numbers
- Trades disclosed
- 17
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 27 Aug 2020
- Last trade
- 1 Jul 2026
- Last filed
- 2 Jul 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jul 2026filed 2 Jul 2026 | VRDN Viridian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,341 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | VRDN Viridian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,341 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,901 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,901 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | JBIO Jade Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —34,843 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | JBIO Jade Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —34,843 at $0.00 | filing |
| 23 Mar 2026filed 25 Mar 2026 | DMRA Damora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,313 at $0.00 | filing |
| 23 Mar 2026filed 25 Mar 2026 | DMRA Damora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,313 at $0.00 | filing |
| 1 Jul 2025filed 2 Jul 2025 | VRDN Viridian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,000 at $0.00 | filing |
| 4 Jun 2025filed 5 Jun 2025 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,700 at $0.00 | filing |
| 29 Apr 2025filed 1 May 2025 | JBIO Jade Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,017 at $0.00 | filing |
| 10 Mar 2025filed 12 Mar 2025 | VRDN Viridian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,000 at $0.00 | filing |
| 5 Jun 2024filed 13 Jun 2024 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,700 at $0.00 | filing |
| 7 Jun 2023filed 8 Jun 2023 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —36,700 at $0.00 | filing |
| 7 Jun 2022filed 9 Jun 2022 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,700 at $0.00 | filing |
| 11 Mar 2021filed 15 Mar 2021 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 27 Aug 2020filed 31 Aug 2020 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,661 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.